Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indium In-111 pentetate is a radiopharmaceutical diagnostic agent composed of the radioactive isotope Indium In‑111 chelated with diethylenetriamine pentaacetic acid (DTPA). It is primarily used for radionuclide cisternography, a nuclear medicine imaging technique to evaluate cerebrospinal fluid (CSF) flow and detect abnormalities such as CSF leaks or blockages. After intrathecal administration, the compound travels with the CSF through the spinal canal and into cranial cisterns, allowing visualization via gamma camera due to photon emissions from Indium‑111 decay. The agent demonstrates efficient renal clearance and minimal background tissue accumulation, resulting in high-quality diagnostic images with low radiation exposure[1][2][3][5]. Its mechanism of action relies on its physical properties as a gamma-emitting tracer rather than pharmacological interaction with biological targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indium in-111 pentetate.